Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

Inclusion Criteria:

5.1.1 Subject Inclusion Criteria

* Age \>18 years
* Advanced NSCLC
* Adequate newly obtained core or excisional biopsy of a recurrent tumor lesion
* Adequate is defined as a biopsy with at least 5 sections tumour tissue available.
* Measurable disease according to RECIST criteria
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Life expectancy \> 3 months
* A tumour lesion suitable for radiotherapy treatment
* Adequate organ function based on clinical examination and lab values (Hb \>9.0, Leucocytes \> 2.0, Trc \> 100, AST/ALT \<3 ULN)
* Women must not be pregnant or breastfeeding
* WOCBP should use an adequate highly effective method to avoid pregnancy for 23 weeks
* For the purpose of this document, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

  * Highly effective contraception methods includes methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:
  * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
  * progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
  * intrauterine device (IUD)
  * intrauterine hormone-releasing system ( IUS)
  * bilateral tubal occlusion
  * vasectomised partner
* sexual abstinence \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half-lives
* Previously untreated or treated NSCLC pts, where treatment with PD1-inhibitor in indicated according to national guidelines.

Exclusion Criteria:

5.1.2 Subject Exclusion Criteria

* Disease suitable for curative salvage surgery
* Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 2 weeks prior to first administration of study drug.
* Significant cardiac, pulmonary or other medical illness that would limit activity or survival
* Pregnancy or lactation.
* Patients with EGFR-mutation or ALK-translocation not treated with tyrosine kinase inhibitor previously
* Known hypersensitivity to any of the components of the investigational product
* Patients who test positive for hepatitis B, C or HIV.
* Known active brain metastases. Patients with stable / treated brain metastases can be included.
* Diagnosis of immunodeficiency or medical condition requiring high doses (\>30 mg prednisolone daily) of systemic steroids or other forms of immunosuppressive therapy
* Any reason why, in the opinion of the investigator, the patient should not participate